



# Bupivacaine hydrochloride in Dextrose Injection USP

## Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)  
Issue date: 2022-11-30

### SECTION 1: Identification

#### 1.1. Product identifier

Product form : Mixture  
Product name : Bupivacaine hydrochloride in Dextrose Injection USP

#### 1.2. Recommended use and restrictions on use

Recommended use : Injection  
Restrictions on use : No data available

#### 1.3. Supplier

Omega Laboratories, Ltd.  
11177 Hamon St.  
Montreal, Quebec H3M 3E4  
Canada  
T (514) 335-0310

#### 1.4. Emergency telephone number

Emergency number : (514) 335-0310

### SECTION 2: Hazard identification

#### 2.1. Classification of the substance or mixture

##### Classification (GHS CA)

Not classified

#### 2.2. GHS Label elements, including precautionary statements

##### GHS CA labeling

No labeling applicable

#### 2.3. Other hazards

No additional information available

#### 2.4. Unknown acute toxicity (GHS CA)

No data available

### SECTION 3: Composition/Information on ingredients

#### 3.1. Substances

Not applicable

# Bupivacaine hydrochloride in Dextrose Injection USP

## Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)

### 3.2. Mixtures

Name	Chemical name / Synonyms	Product identifier	Conc. (% w/w)
Bupivacaine hydrochloride	2-Piperidinecarboxamide, - 1-butyl-N-(2,6-dimethylphenyl)-, monohydrochloride; Bupivacaine HCl	CAS-No.: 14252-80-3	0.73

Full text of hazard classes and H-statements : see section 16

## SECTION 4: First-aid measures

### 4.1. Description of first aid measures

First-aid measures after inhalation	: Remove person to fresh air and keep comfortable for breathing. If you feel unwell, seek medical advice.
First-aid measures after skin contact	: Rinse skin with water/shower. Remove/Take off immediately all contaminated clothing. Wash contaminated clothing before reuse. If skin irritation or rash occurs: Get medical advice/attention.
First-aid measures after eye contact	: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention.
First-aid measures after ingestion	: Get medical advice/attention. Rinse mouth out with water. Never give anything by mouth to an unconscious person.
First-aid measures general	: IF exposed or concerned: Get medical advice/attention.

### 4.2. Most important symptoms and effects (acute and delayed)

Symptoms/effects	: Anesthetic effects. Depression of the central nervous system, headaches, dizziness, drowsiness, loss of coordination.
Symptoms/effects after inhalation	: May cause respiratory irritation.
Symptoms/effects after skin contact	: Repeated or prolonged contact may cause skin irritation.
Symptoms/effects after eye contact	: May cause eye irritation.
Symptoms/effects after ingestion	: May cause irritation to the digestive tract.

### 4.3. Immediate medical attention and special treatment, if necessary

Other medical advice or treatment	: Treat symptomatically.
-----------------------------------	--------------------------

## SECTION 5: Fire-fighting measures

### 5.1. Suitable extinguishing media

Suitable extinguishing media	: Water spray. Dry powder. Foam. Carbon dioxide.
------------------------------	--

### 5.2. Unsuitable extinguishing media

Unsuitable extinguishing media	: No data available.
--------------------------------	----------------------

### 5.3. Specific hazards arising from the hazardous product

Fire hazard	: No fire hazard.
Hazardous decomposition products in case of fire	: Toxic fumes may be released.

### 5.4. Special protective equipment and precautions for fire-fighters

Protection during firefighting	: Do not attempt to take action without suitable protective equipment. Self-contained breathing apparatus. Complete protective clothing.
--------------------------------	--

# Bupivacaine hydrochloride in Dextrose Injection USP

## Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)

### SECTION 6: Accidental release measures

#### 6.1. Personal precautions, protective equipment and emergency procedures

General measures : Ensure adequate ventilation. Wear personal protective equipment. Avoid breathing dust, mist or spray. Mark out the contaminated area with signs and prevent access to unauthorized personnel.

#### 6.2. Methods and materials for containment and cleaning up

For containment : Stop leak, if possible without risk.  
Methods for cleaning up : Take up liquid spill into absorbent material. Collect all waste in suitable and labeled containers and dispose according to local legislation.  
Other information : Dispose of materials or solid residues at an authorized site.

#### 6.3. Reference to other sections

For further information refer to section 8: "Exposure controls/personal protection"

### SECTION 7: Handling and storage

#### 7.1. Precautions for safe handling

Precautions for safe handling : Ensure good ventilation of the work station. Wear personal protective equipment. Avoid contact with skin and eyes. Do not breathe gas, fumes, vapor or spray.  
Hygiene measures : Handle in accordance with good industrial hygiene and safety procedures. Do not eat, drink or smoke when using this product. Always wash hands after handling the product.

#### 7.2. Conditions for safe storage, including any incompatibilities

Storage conditions : Store in a well-ventilated place. Keep container tightly closed. Store at room temperature.

### SECTION 8: Exposure controls/personal protection

#### 8.1. Control parameters

No additional information available

#### 8.2. Appropriate engineering controls

Appropriate engineering controls : Ensure good ventilation of the work station.  
Environmental exposure controls : Avoid release to the environment.

#### 8.3. Individual protection measures/Personal protective equipment

##### Hand protection:

Protective gloves

##### Eye protection:

Safety glasses

##### Skin and body protection:

Wear suitable protective clothing

# Bupivacaine hydrochloride in Dextrose Injection USP

## Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)

### Respiratory protection:

Wear respiratory protection.

### Personal protective equipment symbol(s):



## SECTION 9: Physical and chemical properties

### 9.1. Information on basic physical and chemical properties

Physical state	: Liquid
Appearance	: Liquid.
Color	: No data available
Odor	: No data available
Odor threshold	: No data available
pH	: 4 – 6.5
Relative evaporation rate (butyl acetate=1)	: No data available
Relative evaporation rate (ether=1)	: No data available
Melting point	: Not applicable
Freezing point	: No data available
Boiling point	: No data available
Flash point	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Flammability (solid, gas)	: Not applicable
Vapor pressure	: No data available
Relative vapor density at 20 °C	: No data available
Relative density	: No data available
Density	: 1.031 g/ml
Solubility	: Miscible with water.
Partition coefficient n-octanol/water (Log Pow)	: No data available
Viscosity, kinematic	: No data available
Explosion limits	: No data available

### 9.2. Other information

No additional information available

## SECTION 10: Stability and reactivity

Reactivity	: No additional information available
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: No dangerous reactions known under normal conditions of use.
Conditions to avoid	: No additional information available
Incompatible materials	: Strong acids. Strong bases. Strong oxidizing agents.
Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.
Hardening time:	: No additional information available

# Bupivacaine hydrochloride in Dextrose Injection USP

## Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)

### SECTION 11: Toxicological information

#### 11.1. Information on toxicological effects

Acute toxicity (oral) : Not classified  
Acute toxicity (dermal) : Not classified  
Acute toxicity (inhalation) : Not classified

#### Bupivacaine hydrochloride (14252-80-3)

LD50 oral rat	18 mg/kg
ATE CA (oral)	18 mg/kg body weight

Skin corrosion/irritation : Not classified  
pH: 4 – 6.5  
Serious eye damage/irritation : Not classified  
pH: 4 – 6.5  
Respiratory or skin sensitization : Not classified  
Germ cell mutagenicity : Not classified  
Carcinogenicity : Not classified  
Reproductive toxicity : Not classified  
STOT-single exposure : Not classified  
STOT-repeated exposure : Not classified  
Aspiration hazard : Not classified  
Likely routes of exposure : Dermal. Ingestion. Inhalation.  
Symptoms/effects : Anesthetic effects. Depression of the central nervous system, headaches, dizziness, drowsiness, loss of coordination.  
Symptoms/effects after inhalation : May cause respiratory irritation.  
Symptoms/effects after skin contact : Repeated or prolonged contact may cause skin irritation.  
Symptoms/effects after eye contact : May cause eye irritation.  
Symptoms/effects after ingestion : May cause irritation to the digestive tract.

### SECTION 12: Ecological information

#### 12.1. Toxicity

Hazardous to the aquatic environment, short-term (acute) : Not classified  
Hazardous to the aquatic environment, long-term (chronic) : Not classified

#### 12.2. Persistence and degradability

No additional information available

#### 12.3. Bioaccumulative potential

No additional information available

#### 12.4. Mobility in soil

No additional information available

#### 12.5. Other adverse effects

Ozone : Not classified

# Bupivacaine hydrochloride in Dextrose Injection USP

## Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)

### SECTION 13: Disposal considerations

#### 13.1. Disposal methods

Waste treatment methods : Dispose of contents/container in accordance with licensed collector's sorting instructions.  
Additional information : Flammable vapors may accumulate in the container.

### SECTION 14: Transport information

In accordance with TDG / DOT / IMDG / IATA

TDG	DOT	IMDG	IATA
<b>14.1. UN number</b>			
Not regulated for transport			
<b>14.2. Proper Shipping Name</b>			
Not applicable	Not applicable	Not applicable	Not applicable
<b>Transport document description</b>			
Not applicable	Not applicable	Not applicable	Not applicable
<b>14.3. Transport hazard class(es)</b>			
Not applicable	Not applicable	Not applicable	Not applicable
<b>14.4. Packing group</b>			
Not applicable	Not applicable	Not applicable	Not applicable
<b>14.5. Environmental hazards</b>			
Not applicable	Not applicable	Not applicable	Not applicable
No supplementary information available			

#### 14.6. Special precautions for user

##### TDG

No data available

##### DOT

No data available

##### IMDG

No data available

##### IATA

No data available

#### 14.7. Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

# Bupivacaine hydrochloride in Dextrose Injection USP

## Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)

### SECTION 15: Regulatory information

#### 15.1. National regulations

**Bupivacaine hydrochloride (14252-80-3)**

Not listed on the Canadian DSL (Domestic Substances List)/NDSL (Non-Domestic Substances List)

### SECTION 16: Other information

Issue date : 11-30-2022

Safety Data Sheet (SDS), Canada

This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.